Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) – Stock analysts at HC Wainwright upped their FY2026 earnings estimates for Syndax Pharmaceuticals in a report issued on Tuesday, November 3rd. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($2.06) for the year, up from their prior forecast of ($2.07). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($2.03) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q4 2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.30) EPS, Q4 2027 earnings at ($0.27) EPS, FY2027 earnings at ($1.36) EPS, FY2028 earnings at ($0.08) EPS, FY2029 earnings at $1.54 EPS and FY2030 earnings at $2.42 EPS.
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). Syndax Pharmaceuticals had a negative return on equity of 804.38% and a negative net margin of 72.32%. The business had revenue of $83.30 million during the quarter, compared to analyst estimates of $81.38 million. During the same quarter in the prior year, the company earned ($0.70) EPS. The company’s revenue was up 81.9% on a year-over-year basis.
A number of other brokerages have also commented on SNDX. UBS Group reissued a “buy” rating on shares of Syndax Pharmaceuticals in a report on Thursday, October 1st. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. Weiss Ratings upgraded Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. lowered their price target on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.60.
Get Our Latest Analysis on SNDX
Syndax Pharmaceuticals Price Performance
SNDX stock opened at $10.45 on Thursday. The company has a market capitalization of $925.97 million, a P/E ratio of -4.43 and a beta of 0.48. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 4.69. Syndax Pharmaceuticals has a 52-week low of $9.99 and a 52-week high of $25.59. The business has a 50-day simple moving average of $16.76 and a two-hundred day simple moving average of $20.12.
Insiders Place Their Bets
In related news, Director Dennis Podlesak sold 8,000 shares of the business’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $14.21, for a total transaction of $113,680.00. Following the transaction, the director directly owned 239,763 shares in the company, valued at approximately $3,407,032.23. The trade was a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.80% of the company’s stock.
Institutional Investors Weigh In On Syndax Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth approximately $197,177,000. Bank of America Corp DE purchased a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth approximately $88,426,000. Elmind Capital LP bought a new position in shares of Syndax Pharmaceuticals in the second quarter valued at approximately $40,550,300. Trails Edge Capital Partners LP bought a new position in shares of Syndax Pharmaceuticals in the second quarter valued at approximately $24,264,600. Finally, Algert Global LLC grew its holdings in shares of Syndax Pharmaceuticals by 13.2% in the second quarter. Algert Global LLC now owns 1,051,465 shares of the company’s stock valued at $22,985,000 after acquiring an additional 122,897 shares in the last quarter.
Key Syndax Pharmaceuticals News
Here are the key news stories impacting Syndax Pharmaceuticals this week:
- Positive Sentiment: Third-quarter revenue of $83.3 million topped analyst expectations and rose 81.9% year over year. Coverage also pointed to a Revuforj rebound and a higher Niktimvo margin outlook, supporting the commercial outlook. Article: Syndax misses on EPS but Revuforj rebound and higher Niktimvo margin guide sharpen the commercial story
- Positive Sentiment: Syndax said 19 Revuforj and Niktimvo abstracts were accepted for the ASH 2026 meeting, including seven oral presentations. The data cover revumenib across several acute leukemia settings and longer-term axatilimab results in chronic graft-versus-host disease, offering potential catalysts for investor interest. Article: Syndax highlights acceptance of 19 abstracts at ASH 2026
- Neutral Sentiment: The company appointed Aaron A. Ondrey as chief financial officer as part of a CFO transition. The announcement provides a leadership change but no clear immediate financial or operating impact. Article: Syndax announces CFO transition
- Neutral Sentiment: Syndax plans an investor event during the ASH meeting on December 14, which may give management a platform to discuss its products and pipeline; the event itself does not change near-term results. Article: Syndax to host ASH investor event
- Negative Sentiment: The company’s third-quarter loss per share was $0.55, missing the $0.50 loss analysts expected. Reports also cited pipeline setbacks, weighing against the revenue growth and sharpening concerns about execution. Article: Syndax reports third-quarter earnings results
- Negative Sentiment: Pomerantz LLP announced an investigation into claims on behalf of Syndax investors. The notice may add a legal overhang, though it does not establish wrongdoing. Article: Pomerantz investigates claims on behalf of Syndax investors
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.
Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.
See Also
- Five stocks we like better than Syndax Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
